Big risers include Eli Lilly, Biogen, Moderna and Biontech.
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Acadia becomes the latest to fall foul of the US FDA's apparently increasingly strict stance.
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.